Screener
BioCryst Pharmaceuticals BCRX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 14,818 | 17,182 |
| Total current assets | 484,683 | 404,346 |
| Long-term inventory, net | 31,945 | 23,990 |
| Property and equipment, net | 9,058 | 8,783 |
| Long-term investments | — | 61,164 |
| Right of use assets, net | 12,608 | 10,203 |
| Other assets | 19,557 | 5,672 |
| Total assets | $557,851 | $514,158 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's PP&E (net)?
- BioCryst Pharmaceuticals (BCRX) reported PP&E (net) of $9.06M in Q2 2026.
- How has BioCryst Pharmaceuticals's PP&E (net) changed year-over-year?
- BioCryst Pharmaceuticals's PP&E (net) increased by 7.1% year-over-year, from $8.46M to $9.06M.
- What is the long-term trend for BioCryst Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's PP&E (net) has grown at a 4.3% compound annual growth rate (CAGR), from $7.11M to $8.78M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about BioCryst Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude